Mikhail S. Shchepinov, Trends in Pharmacological Sciences, 2020, doi:10.1016/j.tips.2020.01.010.
Regioselective deuteration that reinforces oxidation-prone, bis-allylic sites of PUFAs is a novel, nonantioxidant treatment modality that dramatically reduces LPO, potentially mitigating numerous diseases through preservation of membrane properties and amelioration of oxidative stress. Animal disease models and several ongoing human clinical trials highlight the potential of the deuterated-PUFA (D-PUFA) drug candidates currently in development.
Thursday, March 5, 2020
Subscribe to:
Posts (Atom)
